Skip to main content
. Author manuscript; available in PMC: 2022 Aug 16.
Published in final edited form as: Neuropharmacology. 2018 Jun 21;138:304–314. doi: 10.1016/j.neuropharm.2018.06.024

Fig. 2.

Fig. 2.

Effects of D1R Agonist SKF38393 and D3R Agonist PD128907 on ALO AIMs (2A + 2B) and rotations (2C + 2D). In a within-subjects, counterbalanced design rats were treated with either D1R agonist SKF38393 (SKF; 0, 0.3, 1.0, 3.0 mg/kg; Fig. A + C) or (PD; 0, 0.1, 0.3, 1.0 mg/kg; Fig. B + D). Animals were rated for ALO AIMs and rotations for 3 h post-injection. AIMs time course and ALO sums are expressed as medians (ALO . median absolute difference; M.A.D.) Rotations time course is expressed as means (rotations + standard error of the mean; S.E.M.). Significant AIMs differences were determined by non-parametric Friedman ANOVAs with Wilcoxon Match Pairs post-hoc tests. Significant rotational differences were determined using parametric repeated measures ANOVAs with LSD post-hoc tests (@p < .05 high vs. vehicle, ^p < .05 middle vs. vehicle, +p < .05 low vs. vehicle).